IntroductionCyclophosphamide (CP) is an antineoplastic agent andimmunosuppressive. It is a drug used in the treatment ofvarious types of tumors, organ transplant rejection, as wellas in treatment of autoimmune diseases such as systemiclupus erythematosus, rheumatoid arthritis and multiplesclerosis [1]. CP is a pro drug which undergoes a metabolicactivation by hepatic microsomal cytochrome P450, pri-marily being oxidized to 4-hydroxycyclophosphamide.This metabolite enters cells and spontaneously decom-poses to phosphoramide-mustard and acrolein [2,3]. Thetherapeutic activity of CP involves alkylation of tumor celland its cytotoxic effect is due to phosphoramide-mustardmetabolite. On the other hand, acrolein is reported tocause toxic effects on normal cells, it activates reactiveoxygen species (ROS) and nitric oxide production, leading